For the Inventor, By the Inventor

Enter assignee name

Bellinzona, Switzerland

Humabs Biomed Sa

USPTO Granted Patents = 37

EPO Patents = 10

Forward Citations = 49

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Davide Corti (37 out of 50 patents)

Antonio Lanzavecchia (9 out of 64 patents)

Ebony Benjamin (7 out of 8 patents)

4. Nicole Kallewaard-LeLay (7 out of 18 patents)

5. Josephine Mary McAuliffe (7 out of 10 patents)

6. Leslie Wachter (7 out of 8 patents)

7. Qing Zhu (7 out of 15 patents)

8. Andy Q Yuan (7 out of 13 patents)

9. Anna DeMarco (5 out of 5 patents)

10. Bret Sellman (4 out of 16 patents)

11. Martina Beltramello (4 out of 6 patents)

12. Elisabetta Cameroni (4 out of 6 patents)

13. Christine Tkaczyk (4 out of 12 patents)

14. Andrea Minola (4 out of 4 patents)

15. Qun Wang (4 out of 5 patents)

37 patents: Sort by Forward Citations

1. 12404318 - Combination HBV therapy (2025-09-02),

2. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),

3. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),

4. 12304946 - Antibodies that neutralize hepatitis B virus and uses thereof (2025-05-20),

5. 12297258 - Antibodies againstspecies (2025-05-13),

6. 12037381 - Antibodies that potently neutralize hepatitis B virus and uses thereof (2024-07-16),

7. 12018068 - Anti-O1 antibodies and uses thereof (2024-06-25),

8. 11970527 - Antibody directed againstclumping factor A (ClfA) (2024-04-30),

9. 11932682 - Neutralizing anti-influenza A antibodies and uses thereof (2024-03-19),

10. 11926658 - Multispecific antibodies specifically binding to Zika virus epitopes (2024-03-12),

11. 11912757 - Antibodies specifically binding to Zika virus epitopes and uses thereof (2024-02-27),

12. 11787853 - Neutralizing anti-influenza b antibodies and uses thereof (2023-10-17),

13. 11730813 - Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof (2023-08-22),

14. 11723977 - Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof (2023-08-15),

15. 11578119 - Antibodies directed againstleukotoxins (2023-02-14),

HUMABS BIOMED SA is a biotechnology company specializing in the discovery and development of fully human monoclonal antibodies for therapeutic applications. With extensive expertise in immunology and antibody engineering, HUMABS BIOMED SA aims to address unmet medical needs and improve patient outcomes. Their innovative approach involves the use of advanced technologies to identify and optimize antibodies with high specificity and efficacy. Through strategic collaborations and partnerships, HUMABS BIOMED SA strives to bring novel antibody-based therapies to market and make a significant impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

37 Patents

#2 in Bellinzona

#361 in Switzerland

#17,736 in the World

Bellinzona, Switzerland

Humabs Biomed Sa

Forward Citations = 49

41 inventors:

Davide Corti (37 out of 50 patents)

Antonio Lanzavecchia (9 out of 64 patents)

Ebony Benjamin (7 out of 8 patents)

4. Nicole Kallewaard-LeLay (7 out of 18 patents)

5. Josephine Mary McAuliffe (7 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…